argenx vs Johnson & Johnson stock
Side by side in plain words: who keeps more of its sales, grows faster, costs less and owes less.
argenx is more profitable, grows faster and has less debt. Johnson & Johnson is cheaper for its profits.
Side by side
| argenx | Johnson & Johnson | |
|---|---|---|
| $58.2 billion | $651 billion | |
| 31.1% | 28.5% | |
| +116.2% | +2.7% | |
| 45.1× | 24.3× | |
| Net cash | 0.7 years | |
| 11.7% | 21.0% | |
| – | 2.3% |
How we compare
Four contests with the same rules as each stock page: profit kept from sales (higher wins), yearly sales growth across the last reports, up to five years (higher wins), price per unit of yearly profit (lower P/E wins; a company without profit loses) and debt in years of earnings (lower wins). A winner is only named when both companies have the number.
More comparisons: argenx vs Eli Lilly · argenx vs Merck & · argenx vs Roche · argenx vs UnitedHealth · Johnson & Johnson vs AstraZeneca · Johnson & Johnson vs Bayer · Johnson & Johnson vs Becton, Dickinson and · Johnson & Johnson vs Bristol-Myers Squibb

